Table 2 Comparison between gender and ischemic stroke subtypes
From: Features of serum fatty acids in acute ischaemic stroke patients aged 50 years or older
Male | Female | p | LAA_SVO | CE_O | p | |
|---|---|---|---|---|---|---|
n = 121 | n = 70 | n = 102 | n = 89 | |||
Age (m ± SD) years | 74.4 ± 10.4 | 74.4 ± 10.7 | ns | 71.86 ± 10.46 | 77.37 ± 9.68 | 0.0002 |
BMI (MD, IQR) kg/m2 | 23.7, 21.6–25.2 | 22.3, 20.1–24.8 | < 0.05 | 22.9, 20.7–24.8 | 23.5, 20.9–25.2 | ns |
Gender | ||||||
Male | 62 | 59 | ns | |||
Female | 40 | 30 | ||||
Lipids | ||||||
T-CHO (m ± SD) mg/dl | 194.6 ± 39.4 | 218.4 ± 37.3 | < 0.0001 | 213.9 ± 41.7 | 191.2 ± 34.8 | < 0.0001 |
LDL-C (m ± SD) mg/dl | 113.5 ± 32.3 | 135.6 ± 31.1 | < 0.0001 | 128.4 ± 34.8 | 113.9 ± 30.4 | 0.0028 |
HDL-C (MD, IQR) mg/dl | 53.5, 42.9–63.6 | 61.8, 50.9–73.9 | 0.0023 | 58.5, 46.4–70.6 | 55.2, 43.7–67.9 | ns |
TG (MD, IQR) mg/dl | 101, 68–163 | 87, 70.5–116.3 | ns | 106.5, 73–166.8 | 85.5, 64–115.8 | 0.0054 |
Saturated Fatty Acids | ||||||
LaA (C12:0) (MD, IQR) μg/ml | 1,2, 0.7–2.7 | 1,2, 0.8–2.0 | ns | 1.3, 0.7–2.6 | 1.1, 0.7–1.95 | ns |
MyA (C14:0) (MD, IQR) μg/ml | 17.6, 13.3–29.7 | 19.2, 14.7–25.3 | ns | 19.75, 14.48–31.9 | 17.5, 13.1–23.6 | ns |
PA (C16:0) (MD, IQR) μg/ml | 678.6, 592.8–829.4 | 702.1, 595.4–756.9 | ns | 717.15, 605.0–833.1 | 648.4, 577.2–724.3 | 0.0023 |
StA (C18:0) (MD, IQR) μg/ml | 195.9, 167.4–229.6 | 211.1, 187.9–236.9 | ns | 210.4, 183.4–240.4 | 193.5, 164.7–221.4 | 0.003 |
LaA (C12:0) (MD, IQR) % | 0.04, 0.03–0.08 | 0.04, 0.03–0.07 | ns | 0.04, 0.03–0.08 | 0.04, 0.025–0.07 | ns |
MyA (C14:0) (MD, IQR) % | 0.64, 0.495–0.935 | 0.64, 0.568–0.768 | ns | 0.65, 0.51–0.933 | 0.64, 0.51–0.84 | ns |
PA (C16:0) (m ± SD) % | 24.05 ± 1.44 | 23.13 ± 1.39 | < 0.0001 | 23.7 ± 1.6 | 23.7 ± 1.3 | ns |
StA (C18:0) (m ± SD) % | 6.89 ± 0.77 | 7.11 ± 0.75 | ns | 6.95 ± 0.79 | 6.99 ± 0.08 | ns |
n-9 Monounsaturated Fatty Acid | ||||||
OlA(C18:1) (MD, IQR) μg/ml | 615.4, 513.6–734.6 | 583.0, 514.8–712.9 | ns | 638.2, 527.8–754.5 | 567.5, 499.4–649.3 | 0.0086 |
OlA (C18:1) (m ± SD) % | 21.63 ± 2.52 | 20.59 ± 2.30 | 0.005 | 21.29 ± 2.46 | 21.21 ± 2.54 | ns |
n-6 Polyunsaturated Fatty Acids | ||||||
LiA (C18:2) (MD, IQR) μg/ml | 782.3, 643.7–919 | 822.4, 681.0–940.4 | ns | 844.65, 698.7–977.48 | 728.5, 636.45–883.7 | 0.003 |
DGLA (C20:3) (MD, IQR) μg/ml | 26.9, 21.0–34.8 | 31.5, 23.6–38.2 | 0.018 | 32, 24.3–38.33 | 24.4, 18.9–31.15 | < 0.0001 |
AA (C20:4) (MD, IQR) μg/ml | 142.2, 114.9–162.3 | 156.3, 136.1–175.1 | 0.0034 | 155.7, 132.53–182.18 | 136.3, 114.05–158.15 | < 0.0001 |
LiA (C18:2) (m ± SD) % | 27.036 ± 3.4 | 27.31 ± 3.35 | ns | 27.06 ± 3.46 | 27.22 ± 3.30 | ns |
DGLA (C20:3) (m ± SD) % | 0.95 ± 0.25 | 1.05 ± 0.29 | 0.0125 | 1.04 ± 0.28 | 0.93 ± 0.24 | 0.0028 |
AA (C20:4) (m ± SD) % | 4.94 ± 1.17 | 5.27 ± 1.00 | 0.0452 | 5.18 ± 1,15 | 4.92 ± 1.07 | ns |
n-3 Polyunsaturated Fatty Acids | ||||||
AlA (C18:3) (MD, IQR) μg/ml | 21.5, 15.3–30.9 | 20.9, 16.4–27.5 | ns | 21.7, 16.13–31.13 | 20.8, 14.75–27.55 | ns |
EPA(C20:5) (MD, IQR) μg/ml | 59.3, 44.7–90.1 | 73.2, 48.6–94.1 | ns | 63, 45.68–92.88 | 62.5, 45.25–92.85 | ns |
DHA (C22:6) (m ± SD) μg/ml | 130.1 ± 43.5 | 148.6 ± 40.4 | 0.0012 | 139.3 + 4.3 | 134.15 + 4.58 | ns |
AlA (C18:3) (MD, IQR) % | 0.7, 0.6–0.99 | 0.72, 0.59–0.89 | ns | 0.71, 0.59–0.99 | 0.72, 0.61–0.95 | ns |
EPA (C20:5) (MD, IQR) % | 2.1, 1.43–3.15 | 2.29, 1.67–3.44 | ns | 2.05, 1.41–3.15 | 2.4, 1.69–3.29 | ns |
DHA (C22:6) (m ± SD) % | 4.47 ± 1.32 | 5.00 ± 1.38 | 0.0094 | 4.53 ± 1.41 | 4.81 ± 1.30 | ns |
EPA / AA ratio (MD, IQR) | 0.45, 0.315–0.6 | 0.455, 0.343–0.6 | ns | 0.43, 0.28–0.59 | 0.48, 0.365–0.68 | ns |
n-6 / n-3 ratio (MD, IQR) | 4.31, 3.445–5.295 | 4.1, 3.14–5.228 | ns | 4.355, 3.428–5.653 | 4.16, 3.21–4.99 | ns |